When Will Biosimilars Start Making a Serious Difference in Oncology? | Managed Healthcare Executive
It's early days yet because patent and other issues have kept FDA-approved biosimilars off the market, but Gary Lyman, M.D., M.P.H.. of the Fred Hutchinson Cancer Research Center says there's...
managedhealthcareexecutive.com